Health information disclaimer: This article is for general information only and is not medical advice. Several drugs discussed here are investigational and not approved for use. Never seek unapproved medications outside of clinical trials, and make treatment decisions only with a licensed healthcare professional. Information is current as of October 2026; approval statuses refer to the US FDA unless noted, and Canadian availability follows separate Health Canada review. Drug availability, coverage, and clinical guidance may differ by province.
Ozempic and Mounjaro were the opening act. Behind them stretches a pipeline of drugs aiming for 25 to 30 percent weight loss, monthly or even less frequent dosing, daily pills instead of injections, and combinations designed to protect muscle while melting fat. Some of these medicines are already approved. Some are months from a regulatory decision. Some are years away.
This is a map of that pipeline as of October 2026: what each drug does, what the trials actually showed, where each stands with regulators, and the honest caveats the hype usually skips. A note on reading the numbers below: weight-loss figures come from different trials with different patients, durations, and statistical methods. They are snapshots, not a ranked leaderboard.
Key takeaways
- Retatrutide (Eli Lilly, triple agonist): 28.3 percent mean weight loss at 80 weeks in Phase 3 TRIUMPH-1; not yet approved, with a filing planned for Q1 2027.
- CagriSema (Novo Nordisk, amylin plus GLP-1): 22.7 percent at 68 weeks in REDEFINE 1; under FDA review with a decision expected late 2026.
- Daily GLP-1 pills are already here: orforglipron (FDA-approved April 2026, up to 11.2 percent) and oral semaglutide (FDA-approved December 2025, about 13.6 percent).
- Monthly dosing is in Phase 3 (Amgen's MariTide), and muscle-sparing antibodies are being tested alongside GLP-1s.
- Cross-trial comparisons are not head-to-head evidence; long-term safety data for pipeline drugs are still limited; Canadian timelines lag US approvals.
The new mechanisms: triple agonists and amylin
Current blockbusters work on one or two hormone pathways: semaglutide targets GLP-1 alone, tirzepatide adds GIP. The next generation adds more levers.
Triple agonists add glucagon to the mix. Glucagon raises energy expenditure, not just appetite suppression, which theoretically adds a second engine to weight loss. Retatrutide is the furthest along: the first triple agonist to complete Phase 3 testing.
Amylin combinations pair a GLP-1 with amylin, a pancreatic hormone that promotes satiety and slows gastric emptying through a separate pathway. The idea is complementary appetite control with potentially better tolerability. CagriSema (cagrilintide plus semaglutide) leads this class, and both Lilly (eloralintide, a selective amylin agonist) and Novo Nordisk (zenagamtide, formerly amycretin, which combines GLP-1 and amylin activity in a single molecule) have follow-ons in development.
The pipeline at a glance (October 2026)
Retatrutide (Eli Lilly). GIP plus GLP-1 plus glucagon; weekly injection. Phase 2 showed 24.2 percent mean weight loss at 48 weeks. The Phase 3 TRIUMPH-1 topline, announced May 2026: 28.3 percent at 80 weeks on the 12 mg dose, with 45.3 percent of that group losing more than 30 percent of body weight. In a pre-planned extension for participants starting with BMI of 35 or higher, average loss reached 30.3 percent at 104 weeks, about 38.5 kg. In TRIUMPH-2, which enrolled 1,152 people with obesity and type 2 diabetes, the 12 mg group lost an average of 22.5 kg over 80 weeks, and roughly six in ten were no longer classified as having obesity by BMI at the end. Status: Phase 3 complete; Lilly plans to file for approval in Q1 2027. Not approved anywhere yet.
CagriSema (Novo Nordisk). Amylin plus GLP-1; weekly injection. REDEFINE 1 (3,417 adults with obesity, no diabetes): 22.7 percent mean reduction at 68 weeks, with about 40 percent of adherent patients losing 20 percent or more. REDEFINE 9 versus placebo: 21.0 percent versus 2.0 percent at 68 weeks. Notably, in the REDEFINE 4 head-to-head against tirzepatide, CagriSema lost: 23.0 percent versus 25.5 percent for tirzepatide, a reminder that new does not automatically mean better. Status: under FDA review; decision expected late 2026.
Orforglipron (Eli Lilly). Small-molecule GLP-1; daily pill. ATTAIN-1: up to 11.2 percent weight loss at 72 weeks. Status: FDA-approved April 1, 2026. The significance is less the number than the format: a pill is cheaper to manufacture, easier to take, and easier to scale globally than an injectable peptide.
Oral semaglutide / Wegovy pill (Novo Nordisk). Daily oral semaglutide taken fasting: about 13.6 percent mean weight loss in trial data reported at approval. Status: FDA-approved December 2025.
Wegovy HD, 7.2 mg semaglutide (Novo Nordisk). Higher-dose weekly injection: 20.7 percent at 72 weeks. Status: FDA-approved March 19, 2026. Proof that there is still headroom in the original molecule.
MariTide (Amgen). GLP-1 agonist plus GIP antagonist; dosed monthly or less often. Phase 2: about 16 to 20 percent at 52 weeks. Status: Phase 3 (MARITIME program) ongoing. The less-frequent dosing is the real innovation if efficacy holds.
Eloralintide (Lilly). Selective amylin agonist; weekly injection. Phase 2: 20.1 percent at 48 weeks. Status: Phase 3 started February 2026.
Zenagamtide, formerly amycretin (Novo Nordisk). GLP-1 plus amylin in one molecule; oral and injectable versions in development. Early trials: about 22 to 24 percent. Status: Phase 3.
The muscle-sparing frontier
One of the most important questions about today's drugs is whether the next generation can shift weight loss further toward fat and away from lean tissue. Two approaches are being explored:
- Amylin-based combinations (CagriSema, eloralintide, zenagamtide), on the theory that complementary satiety pathways may produce "higher quality" weight loss.
- Anti-myostatin antibodies, which directly target muscle-preservation pathways, tested alongside GLP-1s in trials such as Regeneron's COURAGE study.
Honest status check: this is the most exciting and the least proven part of the pipeline. No next-generation drug has yet demonstrated clearly superior muscle preservation in a large published trial, and development is bumpy: Lilly halted its Phase 2b trial of the anti-myostatin agent bimagrumab with tirzepatide in September 2025 for strategic business reasons. Until the data mature, resistance training and adequate protein remain the proven muscle-protection strategies, as the 2026 evidence on GLP-1s and lean mass shows.
Safety signals to watch
The familiar GLP-1 side effects carry over: nausea, vomiting, diarrhoea, and constipation, mostly mild to moderate and concentrated during dose escalation. Retatrutide adds a distinctive signal worth knowing: altered skin sensation (dysesthesia, often described as tingling or burning) occurred in 12.5 percent of the 12 mg group versus 0.9 percent on placebo in TRIUMPH-1, mostly mild to moderate and often resolving during treatment, but 11.3 percent of the 12 mg group discontinued due to adverse reactions overall.
The bigger caveat is structural: Phase 3 trials run for one to two years in selected populations. Rare risks, decade-scale effects, and outcomes in broader real-world populations only emerge after approval, which is why the long safety records of semaglutide and tirzepatide remain a genuine advantage of the current generation.
What this means if you are considering treatment now
Do not wait for the perfect drug. Retatrutide is at least a year from potential US approval, longer for Canada, and CagriSema's edge over existing options is unproven in head-to-head testing. Current drugs have the deepest safety data and, increasingly, lower cash prices.
Pills change the access equation. If injections were the barrier, orforglipron and oral semaglutide deserve a conversation with your clinician, with eyes open about the efficacy trade-off.
Watch the muscle story, but do not bank on it. If preserving lean mass is your priority, especially as an older adult, the proven tools today are strength training and protein, not a pipeline drug.
For Canadians specifically: US approval dates are not Canadian availability dates. Health Canada review status and submission timelines for orforglipron, CagriSema, and retatrutide as of October 2026. Coverage remains the practical gatekeeper: private plans vary widely, and public coverage for anti-obesity medications is limited. Ask your clinician and insurer about current options rather than assuming a newly approved drug is accessible.
Practical next steps
- Discuss options with your clinician, including whether a currently available drug, at the right dose with the right habits, already meets your goals.
- If pills appeal to you, ask specifically about orforglipron and oral semaglutide availability and coverage in your province.
- Do not source investigational drugs outside trials. The pipeline is exciting; the grey market is dangerous.
- Build the habits regardless of which drug generation you use. Protein, resistance training, sleep, and ongoing clinical follow-up determine long-term success far more than which molecule you take.
The bottom line
The next generation is real and impressive: 28 percent weight loss from a triple agonist, amylin combinations under regulatory review, daily pills already approved, monthly dosing in Phase 3. But the honest read is that these are incremental advances on a revolution that already happened, not a second revolution. Cross-trial numbers are not head-to-head proof, long-term safety data are still maturing, and nothing in the pipeline replaces the fundamentals: the right drug for the right patient, with muscle-protecting habits and ongoing care. The future of obesity treatment is brighter than ever. It just is not here yet.
Sources
- OneDayMD, "GLP-1 2.0: The Next Generation of Obesity Drugs" (pipeline table, status as of September 29, 2026): https://www.onedaymd.com/2026/09/GLP-1-next-generation-obesity-drugs.html
- Aju Press, October 1, 2026 (TRIUMPH-1 Phase 3 results: 28.3 percent at 80 weeks, 30.3 percent at 104 weeks, dysesthesia and discontinuation rates): https://www.ajupress.com/view/20261001094070521
- The GLP-1 Daily, "CagriSema vs Tirzepatide vs Retatrutide: Head-to-Head Evidence (2026)" (REDEFINE 1, SURMOUNT-1, Phase 2 comparisons): https://theglp1daily.com/cagrisema-vs-tirzepatide-vs-retatrutide-2026
- GlobeNewswire, September 21, 2026 (Novo Nordisk: CagriSema REIMAGINE 5 and REDEFINE 9 results): https://www.globenewswire.com/news-release/2026/09/21/3365319/0/en/novo-s-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-in-reimagine-5-trial.html
- New York Examiner News (TRIUMPH-2 results in type 2 diabetes population, published in The Lancet): https://newyorkexaminernews.com/science-2/blockbuster-retatrutide-trial-signals-a-new-high-water-mark-for-weight-loss-drugs/
- Totiva Health, "Retatrutide vs Mounjaro vs Wegovy: 2026 UK Comparison": https://www.totiva.co.uk/blog/retatrutide-vs-mounjaro-vs-wegovy-weight-loss-comparison
Quick answers
Frequently asked questions
01
What is retatrutide and how much weight did people lose on it?
Retatrutide is Eli Lilly's investigational triple agonist, targeting GLP-1, GIP, and glucagon receptors in a weekly injection. In the Phase 3 TRIUMPH-1 trial, the 12 mg dose produced an average 28.3 percent weight loss at 80 weeks, rising to 30.3 percent at 104 weeks in an extension for participants with BMI of 35 or higher. About 45 percent of the 12 mg group lost more than 30 percent of body weight. It is not yet approved; Lilly plans to file for approval in Q1 2027.
02
What is CagriSema and when will it be available?
CagriSema is Novo Nordisk's weekly injectable combining cagrilintide (an amylin analogue) with semaglutide. In the Phase 3 REDEFINE 1 trial it produced 22.7 percent mean weight loss at 68 weeks. As of October 2026 it is under FDA review, with a decision expected in late 2026. Availability in Canada would follow a separate Health Canada review, so timelines will differ.
03
Are there weight-loss pills now instead of injections?
Yes. Eli Lilly's orforglipron, a daily small-molecule GLP-1 pill, was FDA-approved on April 1, 2026, with up to 11.2 percent weight loss at 72 weeks in the ATTAIN-1 trial. Novo Nordisk's oral semaglutide (Wegovy pill) was FDA-approved in December 2025 with about 13.6 percent mean weight loss. Pills are less potent than the leading injections but far easier to take and manufacture.
04
Is retatrutide better than Mounjaro?
On raw trial numbers, retatrutide's 28.3 percent at 80 weeks exceeds tirzepatide's 22.5 percent at 72 weeks in SURMOUNT-1, and a head-to-head trial of CagriSema versus tirzepatide actually favoured tirzepatide (23.0 versus 25.5 percent). But these are separate trials with different patients, durations, and methods, not head-to-head comparisons, and retatrutide's long-term safety data are still limited. Treat cross-trial rankings as interesting, not decisive.
05
What are the side effects of the new drugs?
The familiar gastrointestinal effects dominate: nausea, vomiting, diarrhoea, and constipation, similar to current GLP-1 drugs. Retatrutide has an additional notable signal: altered skin sensation (dysesthesia) occurred in 12.5 percent of the 12 mg group versus 0.9 percent on placebo in TRIUMPH-1, and 11.3 percent of the 12 mg group discontinued due to adverse reactions. Long-term safety data are still maturing for all pipeline drugs.
06
Will the new drugs preserve muscle better than current GLP-1s?
That is the goal of several pipeline approaches, including amylin combinations and anti-myostatin antibodies tested alongside GLP-1s, but the evidence is early. No next-generation drug has yet demonstrated clearly superior muscle preservation in a large published trial. Resistance training and adequate protein remain the proven strategies for protecting muscle during weight loss.
